Table 1.

Demographic and clinical characteristics of the NHANES samples and the ORION trials

Characteristic	ASCVD sample (n = 579)	Control one† (n = 781)	ASCVD-risk equivalent sample (n = 382)	Control two‡ (n = 98)
Age — yr	67 ± 10.2	66.4 ± 8.9	63.6 ± 11.5	62.7 ± 10.6
Male sex — no.(%)	359(62)***	535(68.5)	219(57.3) ***	45(45.9)
White race — no.(%)	341(58.9) ***	653(83.6)	142(37.2) ***	94(95.9)
Cardiovascular risk factors — no.(%)
ASCVD	579(100)	781(100)	0(0)	0(0)
Current smoker	127(21.9) ***	123(15.7)	68(17.8)	19(19.4)
Hypertension	438(75.7) ***	714(91.4)	264(69.1)	67(68.4)
Diabetes	190(32.8) ***	371(47.5)	208(54.5) ***	66(67.3)
10-year predicted CVD risk ≥ 20%	/	/	287(75.1) ***	54(55.1)
Lipid measures — mg/dL
LDL cholesterol	103.2 ± 28	104.5 ± 39.6	128.8 ± 25.8***	143.1 ± 65.7
Total cholesterol	181.6 ± 35.9	180.6 ± 46.1	210.2 ± 30.9***	232 ± 69.6
Non-HDL cholesterol	131.2 ± 34.3**	134 ± 44.5	158.6 ± 31.1***	177.9 ± 69.6
HDL cholesterol	50.3 ± 14.3**	46.6 ± 14.3	51.7 ± 13.7*	50.3 ± 15.5
Triglycerides	125 (87–175)	127 (92–181)	136 (95–188)***	159 (115–204)

Quantitative variables are presented as mean ± standard deviation, except for triglycerides, which are reported as median (interquartile range) due to its non-normal distribution. Qualitative variables are expressed as numbers (percentages). The characteristics of the inclisiran groups in the ORION trials are provided for comparison with the NHANES eligible samples

† Control 1: ASCVD patients treated with inclisiran in the ORION-10 trial

‡ Control 2: ASCVD-risk equivalent subjects treated with inclisiran in the ORION-11 trial

*P < 0.05, **P < 0.01, ***P < 0.001

Abbreviations NHANES, National Health and Nutrition Examination Survey; ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein